Physician profile
Maxim V Mirovski
NPI 1689797847
$3,772.45
in general payments reported to CMS, 2019-2025
31 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $784 · 2020: $140 · 2021: $462 · 2022: $719 · 2023: $837 · 2024: $463 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,528 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.24 |
| Education | $138.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.48 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $481.68 | 2019-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $312.60 | 2019-2023 | Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $230.23 | 2021-2024 | |
| Amgen INC. | $201.84 | 2022-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $180.48 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $168.03 | 2019-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $161.07 | 2022-2023 | Benlysta |
| Ardelyx, INC. | $141.73 | 2023-2025 | Ibsrela |
| Vifor Pharma, INC. | $123.15 | 2019-2024 | Veltassa |
| Takeda Pharmaceuticals U.S.A., INC. | $122.26 | 2020-2023 | Livtencity |
| Bard Peripheral Vascular, INC. | $117.05 | 2025 | |
| Alexion Pharmaceuticals, INC. | $113.39 | 2022 | |
| Akebia Therapeutics INC | $111.86 | 2019-2023 | Auryxia |
| Ultragenyx Pharmaceutical INC. | $95.08 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $83.36 | 2023-2024 | |
| Aurinia Pharma U.S., INC. | $79.93 | 2021-2022 | |
| Veloxis Pharmaceuticals, INC. | $77.71 | 2019-2023 | Envarsus |
| Mallinckrodt Enterprises LLC | $56.81 | 2019 | |
| Ani Pharmaceuticals, INC. | $55.99 | 2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $51.26 | 2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $33.20 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.67 | 2023 | |
| Genzyme Corporation | $24.39 | 2021 | |
| Daiichi Sankyo INC. | $24.38 | 2019 | |
| Apellis Pharmaceuticals, INC. | $24.01 | 2025 | Empaveli |
| Lilly USA, LLC | $20.33 | 2024 | Jardiance |
| Akcea Therapeutics, INC. | $19.71 | 2019 | |
| Baxter Healthcare | $17.54 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2023 | Jardiance |
| Shire North American Group INC | $16.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maxim Mirovski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.